RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic ® for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects on long-term anti-retroviral therapy (ART), despite a median duration of HIV infection of 21 years and baseline CD4 T-cell counts prior to SB-728-T treatment of <500 cells/µl. The data were presented at a translational medicine meeting organized by The Lancet and Cell publications and entitled, "What Will it Take to Achieve an AIDS-Free World?" which is being held in San Francisco, November 3-5, 2013.
"These data are very promising and demonstrate the important link between SB-728-T treatment and immune reconstitution of central memory and total CD4 T cells and lower HIV DNA levels in subjects at 12 months," said Rafick-Pierre Sekaly, Ph.D., Co-Director & Chief Scientific Officer, The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), who presented the data and whose laboratory carried out the immunologic analyses.
ART successfully suppresses viral load in most subjects, but a significant proportion, so called immunologic non-responders (INR), do not restore normal CD4 counts above 500 cells/µl. HIV-infected subjects who were classified as INR, enrolled in Sangamo's ongoing SB-728-902 clinical trial (Cohorts 1-3), received a single infusion of SB-728-T which resulted in a durable increase in total CD4 T-cells associated with increases in ZFN-modified CD4 central memory T-cells, specifically memory and stem cell-like cells (TSCM) which provide a long-lasting source of CCR5-modified CD4 T-cells. Notably, despite the increase in total CD4 T-cells, a long-term decrease in the peripheral blood mononuclear cell (PBMC) HIV reservoir was observed, as measured by proviral DNA using a sensitive assay technique.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV